2009-12-07
James
Lawson
23
2059
2050
Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease
2006-09
Note that the epsilon in this component is a random variable with a mean of 0 and a standard deviation sigma= 4 ADASC units. However in the CellML we have to represent this as a constant value - at least for now - because as yet there is no way of representing a random variable. Possible solutions to this problem are currently being discussed and will probably involve SED-ML.
This component has been included to match the published paper. However in the CellML model it is a bit redundant because population statistics are not considered - at least not yet.
Lockwood
P
Holford
N
Pharmaceutical Research
keyword
Ewy
W
Auckland Bioengineering Institute
The University of Auckland
PKPD
pharmacokinetic pharmacodynamic model
16906456
D
Hermann
j.lawson@auckland@auckland.ac.nz